Evidence map›Paper›PMID 28685276›Full record

ArticleMedical oncology (Northwood, London, England)2017

Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients.

Dilsa Mizrak Kaya, Xiaochuan Dong, Graciela M Nogueras-González, Yan Xu, Jeannelyn S Estrella, Kazuto Harada, Anthony Lopez, Fatemeh G Amlashi, Wayne L Hofstetter, Dipen M Maru and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Dilsa Mizrak KayaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Xiaochuan DongDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Graciela M Nogueras-GonzálezDepartment of Biostatistics, The University of Texas MD Anderson Cancer, Houston, TX, USA.
Yan XuDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Jeannelyn S EstrellaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kazuto HaradaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Anthony LopezDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Fatemeh G AmlashiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Wayne L HofstetterDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dipen M MaruDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Quynh-Nhu NguyenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey H LeeDepartment of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brian WestonDepartment of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manoop S BhutaniDepartment of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeremy J ErasmusDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Irene ThomasDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Jane E RogersDepartment of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shumei SongDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA. jajani@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

Resectable esophageal adenocarcinoma (EAC) patients often receive chemoradiation followed by surgery. However, most patients experience recurrences. Overexpression of MTDH, an oncoprotein with multiple functions, has been found to be associated with poor prognosis in breast cancer, glioblastoma, melanoma and various gastrointestinal malignancies, but not in EAC. We sought to establish its role in resistant EAC (post-treatment residual EAC). MTDH was assessed by immunohistochemistry in resected EAC, and results were correlated with clinical outcomes. MTDH expression was detectable in 72.5% (50/69) of patients, while expression levels were high (positive) in 50.7% (35/69). Of 69 patients analyzed, 25 had no relapse and 44 patients had a relapse (8 with local-regional and 36 with distant). The median follow-up duration was 3 years (0.4-11.6). The median overall survival was not associated with MTDH status (2.79 years for MTDH-negative and 3.60 years for MTDH-positive patients, p = 0.121). In addition, MTDH was not associated with either the type of relapse (local or distant), baseline clinical stage, tumor grade, presence of signet ring cells, surgical (yp) stage, percentage of residual EAC or presence of lymphovascular invasion. Our data reveal that MTDH is not a prognostic biomarker in resistant EAC after trimodality therapy.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCell Adhesion MoleculesEsophageal NeoplasmsFemaleHumansImmunohistochemistryMaleMembrane ProteinsMiddle AgedNeoplasm Recurrence, LocalPrognosisRNA-Binding ProteinsBiomarkers, TumorCell Adhesion MoleculesMembrane ProteinsMTDH protein, humanRNA-Binding ProteinsCancer biomarkerEsophageal adenocarcinomaMTDHRecurrence

Identifiers

PMID28685276
OpenAlexW2734004514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.